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Abstract
Background: Preschool children with recurrent wheezing suffer high morbidity. It is unclear whether objective 
measures of asthma control, such as pulmonary function tests (PFTs), provide additional information to the 
clinical assessment.
Methods: We recruited children between 3-6 years old, with a history of recurrent wheezing in the preceding 
year and treated for acute wheezing exacerbation in the Emergency Department (ED) into an observational 
cohort study. Children attended two outpatient visits: the first study visit within five days of discharge from the 
ED and the second study visit 12 weeks after the ED visit. We performed standardized symptom score (Test for 
Respiratory and Asthma Control in Kids (TRACK)), multiple breath washout (MBW), spirometry, and clinical 
assessment at both visits.
Results: Seventy-four children, mean (standard deviation (SD)) age 4.32 years (0.84), attended both visits. 
Paired FEV0.75 and LCI measurements at both time points were obtained in 37 and 34 subjects respectively. 
Feasibility for all tests improved at visit 2 and was not age dependent. At the second study visit, a third had 
controlled asthma based on the TRACK score, and the mean lung clearance index (LCI) improved from 9.86 to 
8.31 (p = 0.003); however, 46% had an LCI in the abnormal range. FEV0.75 z-score improved from -1.66 to -
1.17 (p = 0.05) but remained in the abnormal range in 24%. LCI was abnormal in more than half of the children 
with “well-controlled” asthma based on the TRACK score. There was no correlation between PFT measures 
and TRACK scores at either visit. 
Conclusions: LCI demonstrates a persistent deficit post-exacerbation in a large proportion of preschoolers with 
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INTRODUCTION
Asthma is the most common chronic disease in children, imposing a high burden on the health system through 
frequent emergency department (ED) visits, hospital admissions and repeated treatment bursts.1
Despite a decline in asthma hospitalization rates in children and youth by 50% over the past decade in Canada, 
preschoolers under the age of five continue to experience significantly higher rates of hospitalization than 
children over the age of 5 years.2 Diagnosis of asthma in preschoolers is challenging, leading to delays in 
treatment. Yet it is well known that 75% of all asthmatics, trace their onset of wheeze to the first three years of 
life3-5 and persistence of wheeze symptoms is the strongest preschool risk factor for asthma. Furthermore, 
persistent wheezing in preschool children is associated with significant morbidity, high levels of atopy, 
bronchial hyper-responsiveness, and impaired lung function.3 
Preschool children suffering from recurrent wheezing exacerbations and who have persistence of symptoms 
suffer from a significant loss of pulmonary function between preschool and mid-school age.6,7 Few studies 
have examined the utility of pulmonary function tests (PFT) measures for monitoring preschool children with 
wheezing disorders.8,9 Spirometry-derived forced expiratory volume in one second (FEV1) is the most 
commonly reported PFT measure in asthma10. Reduced FEV1 is associated with asthma severity and predictive 
of exacerbations in older children and persistence of symptoms into adulthood.11 Multiple breath washout 
(MBW) has gained attention due to its relative ease of use in preschool children. Lung clearance index (LCI), 
the primary outcome measure of MBW, provides a sensitive estimate of ventilation heterogeneity.
The clinical value of LCI in preschool children with wheezing disorders is not clearly established in the 
existing literature. A British cross-sectional study of preschoolers with wheeze reported that LCI was more 
sensitive than spirometry at detecting abnormal pulmonary function, and could differentiate between viral 
wheeze and multi-trigger wheeze.8 However, a Danish cross-sectional study reported that LCI did not 
discriminate between preschool children in the community with wheezing symptoms and healthy controls.9 
Most recently, another Danish study suggested that preschool LCI may detect children with wheezing 
syndromes who experiencing more severe exacerbations.12 
Given the discrepancy between symptoms scores and clinical outcomes and the potential role of PFTs, we 
designed an observational cohort study, the WheezyER study, to evaluate preschool pulmonary function 
changes over a 12 week period amongst children identified during an acute wheezing exacerbation and to 
evaluate its added value to clinical assessment of symptoms. Our research group has also studied changes in 
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monitoring CF lung disease.13 We also compared changes in LCI measures and FEV0.75 z-score (a more 
sensitive measure of airflow obstruction and disease control in preschool children compared to FEV1)14 to 
similarly timed measurements from our published healthy control data.13 
METHODS
The study was approved by the Hospital for Sick Children Research Ethics Board (REB 1000041089, 
ClinicalTrials.gov ID: NCT02743663), and informed consent was obtained from a parent or legal guardian. 
This was a prospective single-centre observational cohort study. The primary objective was to evaluate changes 
in PFT outcome measures, namely FEV0.75 z-scores and nitrogen washout-based LCI, during acute wheezing 
exacerbations, and to determine whether they provided additional clinical information about preschool 
wheezing exacerbations not captured by symptom assessment alone. Please refer to the Online Supplement for 
a detailed account of the Methods.
RESULTS
Study Population
We screened 575 patients attending the ED and enrolled 100 preschool children with recurrent wheezing in our 
WheezyER study, 20 of whom took part in the pilot study and 80 were assigned to the final WheezyER study. 
Out of the 80 enrolled, symptoms data was missing for six; hence, 74 (92.5%) were included in the analysis 
(see Figure 1 for details). The participant demographics at the first study visit are shown in Table 1. 
Most children (58%, 39/67) had at least one parent with a diagnosis of asthma (Table 1). Almost 80% of the 
children (57/74) had a diagnosis of food allergy, allergic rhinitis, or atopic dermatitis, and more than half 
(40/68) had positive allergy skin tests (Table 1). 
A third of the children (31%, 23/74) had an additional presentation to the ED for acute wheezing between the 
first and second study visit. Standard medical therapy for acute exacerbation of asthma15 (salbutamol, 
ipratropium bromide) was administered to all children at the additional ED visit, furthermore all but one child 
was treated with an additional course of OCS at the ED visit. These children had atopic characteristics similar 
to the rest of the preschool wheeze cohort. There were no significant differences in clinical parameters among 
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TRACK score
Most children (88%, 65/74) had parent-reported TRACK scores suggestive of uncontrolled symptoms at the 
first study visit [mean (SD) score of 52.64 (22.10)] (Table 2). Twelve percent (9/74) of parents reported 
TRACK scores in the “controlled” symptoms range at their first study visit despite their child’s recent visit to 
the ED (Table 1). At the second study visit (12±2 weeks after the ED visit), most children (66%, 49/74) had 
TRACK scores that remained in the uncontrolled symptoms range [mean (SD) score 65.00 (20.34)]. Treatment 
with inhaled corticosteroids (ICS) did not impact this outcome: 44% (11/25) of children with “controlled” 
symptoms and 55% (27/49) of those with “uncontrolled” symptoms received ICS treatment (p = 0.51). 
Between the two study visits, the mean TRACK score improved by a mean (SD) score of 12.4 (22.4), p<0.001. 
The majority of children (58%, 43/74) experienced an improvement in symptoms.
Pulmonary Function Tests
The feasibility of the preschool PFTs is shown in Table 2. Feasibility was not age dependent and was similar 
for spirometry and MBW at the first study visit and improved by the second study visit. Paired longitudinal 
measures were achieved in 50% (37/74) and 46% (34/74) of children for FEV0.75 and LCI measures, 
respectively. The characteristics of this subcohort were similar to the overall cohort (Table E2). 
Spirometry – FEV0.75 z-score
FEV0.75 z-scores improved between the two visits (Table 2). Almost 40% (17/44) had an abnormally low 
FEV0.75 z-score ( -1.96) at the first study visit and FEV0.75 z-score was low in a quarter (13/53)  at the second ≤  
study visit. 
The generalized linear mixed-effect model with repeated measure was used to compare the changes in FEV0.75 
between preschool children with wheeze and healthy controls; the difference between the two groups was 
statistically significant (p=0.02). 
MBW
LCI measures improved from the first study visit to the second study visit in the 34 children with paired 
measures (Table 2). At the first study visit, the mean (SD) LCI was 9.86 (1.88) and 80% (32/40) of children 
had an LCI value greater than the upper limit of normal (ULN = 8), as defined in our published healthy control 
data.13 At the second study visit, the mean (SD) LCI  was 8.31 (1.19); however, 46% (23/50) had an LCI in the 
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ED visits in the year preceding recruitment compared to those with LCI within the normal range (median 5 vs 
3, p=0.02). No other differences in clinical characteristics, including ICS use, atopy, family history, or ED 
visits within the study period was noted between the groups.
Among the subcohort of 34 children with valid LCI measures at both visits, LCI improved significantly by a 
mean of 1.11 (SD 1.99, p = 0.002) (Table 2). Using a generalized linear mixed-effect model with repeated 
measures, the change in LCI over the two visits in preschool children with wheeze was significantly different 
from that seen in the healthy controls (p<0.001). Moment ratios (M0/M1, and M0/M2) were less sensitive to 
airway disease than LCI and therefore, did not add any additional information to LCI alone (See supplemental 
material).
TRACK score & PFT Outcome Measures
LCI, FEV0.75 z-scores, and TRACK scores all improved significantly between the two visits (Table 2). 
However, there were no significant correlations between TRACK scores and either LCI (ρ = 0.26, p = 0.11) or 
FEV0.75 z-scores (ρ = 0.04, p = 0.82) (Figure 2). There was also no correlation between LCI and FEV0.75 z-
scores (ρ = -0.24, p = 0.05). This finding is illustrated in Figure 3. At the second study visit, 25 (66%, 25/38) 
children had “controlled symptoms on TRACK score (  80). Among this group, LCI was abnormal in 40% 
(10 children) and FEV0.75 z-score was abnormal in 8% (2 children). 
Paired Spirometry & MBW Measures
At the first study visit, 24 children had paired FEV0.75 and LCI measurements (Figure 3a). Twenty-three (96%) 
had abnormal PFT results, defined as LCI greater than ULN and/or FEV0.75 z-score below the lower limit of 
normal (≤ LLN). Abnormal LCI measures were recorded in 83% (20/24), and abnormal FEV0.75 z-scores in 
29% (7/24), and 17% (4/24) showed abnormalities in both measures (Figure 3a). 
At the second study visit, 38 children had paired FEV0.75 and LCI measurements. Twenty-one (55%) had 
abnormal PFT results. Abnormal LCI measures were recorded in 45% (17/38), and abnormal FEV0.75 z-scores 
in 18% (7/38), and 8% (3/38) showed abnormalities in both measures (Figure 3b).
Of the 34 children with LCI measures at both visits, 16 (47%) had persistently abnormal LCI values. Of the 37 
children who had spirometry measures at both visits, five (14%) had persistently abnormal FEV0.75 
measures. Nineteen children had paired LCI and FEV0.75 measures at baseline and follow-up, but only one 
(5%) subject had persistently abnormal LCI and FEV0.75, at both visits. There were no evident patterns in 
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DISCUSSION
This study showed that almost half of preschool children with recurrent wheezing who had parent-reported 
“well-controlled” asthma symptoms using the TRACK score demonstrated an abnormal LCI measure, which is 
consistent with existing literature.16,17 In contrast to the literature,9,12,18 we observed significant differences in 
LCI between preschool children with recurrent wheezing and healthy controls. Notably, previous studies 
focused on children from the general population or in asthma clinics, where the preschool wheezing phenotype 
may have been milder or well controlled. A recent publication, using a similar LCI methodology, supports the 
observation that LCI may be more discriminative in children with more severe or symptomatic disease.12 Our 
population had a greater proportion of children who had received oral corticosteroids or suffered from repeated 
exacerbations, which represents a more severe preschool wheeze phenotype. We also found an association 
between abnormal LCI and ED visits for an acute wheezing exacerbation in the previous 12 months, which is 
suggestive of a correlation with disease severity.19 Finally, LCI was feasible in the majority (68%) of our 
children at the second study visit and improved with training and age, a finding previously reported in the 
literature.18 Taken together, preschool LCI measurement is feasible during monitoring visits and offers 
complementary insights into the control of recurrent wheezing disorder in preschool children that are not 
available using symptom scores alone.
The management of preschool recurrent wheezing is controversial and has been the subject of four separate 
guidelines.  Most of the controversy surrounds the diagnosis of asthma due to the heterogeneity in wheeze 
phenotypes as well as response to treatment.  However, despite these controversies, all guidelines consistently 
urge close monitoring between exacerbations. In this age group, symptom monitoring through standardized 
symptom assessment is promoted. However, our study offers some insights into the limitations of this 
approach. We found that at their second visit, after recovery from an exacerbation, 16/50 (40%) children had 
abnormal LCI values despite reporting good symptom control. Overall, our study demonstrates that markers of 
abnormal lung physiology are present despite parental assessment of good control, suggesting that 
incorporation of physiologic outcomes may provide a more comprehensive assessment of preschool recurrent 
wheezing. Whether these additional measures are modifiable with treatment and the resultant impact on clinical 
outcomes should be the focus of future studies. We are unable to comment on the nature of the relationship 
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In our study, more abnormalities were detected using LCI measurements compared to FEV0.75; a quarter 
(13/53) of children had abnormal FEV0.75 and 52% had an abnormal LCI at the second study visit. In those with 
“well-controlled” asthma symptoms on TRACK score at the second study visit, half (53%) had an abnormal 
LCI measure and 10% an abnormal FEV0.75 z-score. It is unclear whether abnormalities in MBW are of clinical 
significance, and given the size of the pilot study, no clinical recommendations may be made. However, it does 
highlight the need for further assessment of the role of MBW at detecting patients who may benefit from more 
aggressive managements strategies, including preventative interventions, such as immunization and public 
health measures to reduce environmental tobacco smoke exposure. 
This study has limitations that warrant consideration. Firstly, the second study visit period was relatively short. 
A longer interval between study visits is needed to assess whether the abnormal LCI values are predictive of a 
severe asthma phenotype or if the resolution of abnormalities requires a more extended period. Furthermore, 
this study was not designed to assess response to a trial of standardized therapy. Therefore, we cannot comment 
on the responsiveness of LCI to standardized treatment. In addition, information regarding exacerbations 
between the two study visits was only available for those children who attended the ED; hence, unreported 
milder exacerbations may have been missed.  Finally, we did not perform sputum, exhaled nitric oxide, or 
urinary analyses of inflammatory markers. Hence, we cannot comment on the relationship between PFT 
outcomes and inflammation in preschoolers with wheeze. 
LCI and FEV0.75 are the PFT measures evaluated in this study. The former is a marker of global ventilation 
inhomogeneity, including peripheral airways, end-bronchioles, and alveolar spaces, whereas the latter measure 
is primarily derived from the central airways. This difference is highlighted in the current study by the findings 
of persistently abnormal LCI measures in a higher portion of children compared to FEV0.75 (47% vs 14%). The 
use of spirometry is well-established in the management of asthma. MBW-derived LCI is being increasingly 
used in the clinical settings for the management of patients with CF and as discussed previously there is an 
increasing interest in its use in the paediatric asthma population, particularly given the evidence suggesting that 
MBW is a more sensitive marker of disease activity than FEV1 in CF. The pathophysiology of CF and asthma 
are very different. Whereas the former affects both airways and the parenchyma due to inflammatory and 
infective process, the latter is primarily a disease of the airways. Hence, findings in CF are not directly 
applicable to asthma. Nevertheless, there is increasing evidence of the utility of MBW in asthma, particularly 
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Larger multi-centre studies are needed to assess the role of MBW in the clinical management of preschool 
children with asthma. Magnetic resonance imaging (MRI) of the lungs is a rapidly advancing imaging 
modality, which can provide regional functional and anatomical lung data. Recently, a number of small studies 
have shown correlation between quantitative and enhanced functional MRI biomarkers and MBW and 
spirometry abnormalities in paediatric and adult patients with CF20,21 and adults with asthma.22 Insight derived 
from the combination of these complementary multi-modality techniques is greater than the sum of individual 
modalities. This is an exciting avenue for future clinical trials as multi-modality biomarkers of disease will 
facilitate personalized precision medicine and individualized targeted therapy.
In conclusion, we have demonstrated that PFT outcomes are abnormal in a significant number of preschool 
children with wheezing three months post-ED visit for acute wheeze exacerbation. This indicates that symptom 
scores alone are insufficient for monitoring recovery from severe exacerbations in a select cohort of 
preschoolers with asthma, and PFT outcomes could provide additional insight into preschool asthma control 
beyond symptom assessment alone. Further studies utilizing multi-modality biomarkers that characterize both 
the lung physiology and inflammation are necessary to improve our understanding of the heterogeneity of 
wheezing phenotypes in this age group. 
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Tables











Male : Female 46 (62%) : 28 (38%)
Age+ in years 4.32 (0.84)
Height z-score ‡ -0.11 (0.97)
Weight z-score ‡ 0.20 (1.00)
BMI z-score ‡ 0.38 (1.06)
Maternal history of asthma n/N (%) 24/70 (34%)
Paternal history of asthma, n/N (%) 21/68 (31%)
Environmental tobacco smoke exposure, n/N (%) # 20/73 (27%)
Atopic sensitization, n/N (%) 40/68 (59%)
Food allergy, n/N (%) 27/73 (37%)
Aeroallergen sensitization, n/N (%) 35/68 (51%)
Oral corticosteroids in the past year , n/N (% ≥ 2 courses) 41/74 (55%)
ED visits for wheezing in the past year, n/N (%) 61/74 (82%)
Continuous inhaled corticosteroids use in the past year, 
n/N (%)
24/74 (32%)
TRACK  80 at acute exacerbation, n/N (%) 9/74 (12%)
* Unless otherwise specified, all values are expressed as mean with standard deviation. Denominators in 
categorical values represent the number of children without missing data. 
+ N=74
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# Environmental tobacco smoke (ETS) exposure is defined as positive if a parent is currently smoking or one or 
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Table 2. Symptom scores and pulmonary function testing outcomes* in WheezyER participants from First to 
Second study visits.
* Values are presented as mean and standard deviation. A generalized linear mixed-effect model with repeated 





Second study visit (Recovery) Changes between Two Visits
Variable Feasibility Measure Feasibility Measure N Paired Raw Changes P-value
TRACK 74/74 (100%) 52.64 (22.10) 74/74 (100%) 65.00 (20.34) 74 12.36 (22.38) <0.001
FEV0.75 z-score 44/74 (59%) -1.66 (1.24) 53/74 (72%) -1.17 (1.18) 37 0.45 (1.34) 0.05
LCI 40/74 (54%) 9.86 (1.89) 50/74 (68%) 8.31 (1.19) 34 -1.09 (1.98) 0.003
FRC 40/74 (54%) 0.68 (0.15) 50/74 (68%) 0.71 (0.14) 34 0.01 (0.12) 0.49
M0/M1 40/74 (54%) 2.14 (0.38) 50/74 (68%) 1.85 (0.22) 34 -0.19 (0.37) 0.004
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Figure Legends
Figure 1. Consort diagram of patients enrolled in the WheezyER study.
Figure 2. Correlation between lung function outcomes at both visits and symptom scores. Horizontal 
hatched lines represent the cut offs of abnormal LCI (≥ 8) or abnormal FEV0.75 z-score (≤-1.96). 
Vertical hatched lines represent TRACK scores at 80, with scores ≥ 80 indicative of controlled 
symptoms: (a) TRACK score and LCI at the first study visit; (b) TRACK score and LCI at the second 
study visit; (c) TRACK score and FEV0.75 z-score at the first study visit; (d) TRACK score and 
FEV0.75 z-score at the second study visit.
Figure 3. Correlation between: (a) LCI and FEV0.75 z-score at the first study visit within 5 days of ED 
presentation, and (b) LCI and FEV0.75 z-score the second study visit.
Figure 4.- Paired longitudinal measures (LCI and FEV0.75 z-score) at visit 1 and 2: (a) FEV0.75 z-score 
at the first and second study visits and (b) LCI at the first and second study visits. Vertical lines 











575 patients were approached between July 
2014 and October 2017.
338 potential patients eligible for screening
Excluded n=237:
• Declined participation - n=230
• Out of recruitment window - n=7
Excluded 238 ineligible patients
• Not diagnosed with asthma - n=156
• Did not meet age criteria (3 to 6 years) - n=6
• <2 wheezing episodes in the last year - n=37
• Salbutamol was not administered within 4 hours before 
or during the ED visit or was not prescribed/administered 
post-discharge - n=5
• No current wheeze - n=2 
• Born pre-term (< 35 weeks gestational age) - n=3
• History of renal, chronic pulmonary, cardiac, neurological, 
or systemic disease - n=3
• Insufficient command of the English language - n=1
• Met > 1 exclusion criterion - n=25
100 patients enrolled in the WheezyER study
74 patients included in the analysis
Not included in this analysis:
• Pilot cohort - n=20
• Missing data in reporting symptoms - n=6
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